KHIRON LIFE SCIENCES CORP (KHRN.CA) Fundamental Analysis & Valuation
TSX-V:KHRN • CA49374L3065
Current stock price
0.04 CAD
0 (0%)
Last:
This KHRN.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. KHRN.CA Profitability Analysis
1.1 Basic Checks
- In the past year KHRN has reported negative net income.
- KHRN had a negative operating cash flow in the past year.
1.2 Ratios
- The profitability ratios for KHRN are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Gross Margin value of 19.51%, KHRN perfoms like the industry average, outperforming 47.73% of the companies in the same industry.
- In the last couple of years the Gross Margin of KHRN has declined.
- The Profit Margin and Operating Margin are not available for KHRN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.81%
GM growth 5YN/A
2. KHRN.CA Health Analysis
2.1 Basic Checks
- KHRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, KHRN has more shares outstanding
- Compared to 1 year ago, KHRN has a worse debt to assets ratio.
2.2 Solvency
- KHRN has an Altman-Z score of -5.28. This is a bad value and indicates that KHRN is not financially healthy and even has some risk of bankruptcy.
- KHRN's Altman-Z score of -5.28 is on the low side compared to the rest of the industry. KHRN is outperformed by 70.45% of its industry peers.
- KHRN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
- KHRN's Debt to Equity ratio of 0.05 is fine compared to the rest of the industry. KHRN outperforms 68.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.28 |
ROIC/WACCN/A
WACC6.71%
2.3 Liquidity
- KHRN has a Current Ratio of 1.91. This is a normal value and indicates that KHRN is financially healthy and should not expect problems in meeting its short term obligations.
- KHRN's Current ratio of 1.91 is in line compared to the rest of the industry. KHRN outperforms 59.09% of its industry peers.
- A Quick Ratio of 0.91 indicates that KHRN may have some problems paying its short term obligations.
- KHRN has a Quick ratio (0.91) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 0.91 |
3. KHRN.CA Growth Analysis
3.1 Past
- KHRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.04%.
- KHRN shows a strong growth in Revenue. In the last year, the Revenue has grown by 38.20%.
- Measured over the past years, KHRN shows a very strong growth in Revenue. The Revenue has been growing by 143.00% on average per year.
EPS 1Y (TTM)-59.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.56%
Revenue 1Y (TTM)38.2%
Revenue growth 3Y143%
Revenue growth 5YN/A
Sales Q2Q%-3.82%
3.2 Future
- KHRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.
- KHRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.15% yearly.
EPS Next Y39.13%
EPS Next 2Y31.88%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year36.43%
Revenue Next 2Y38.09%
Revenue Next 3Y45.7%
Revenue Next 5Y40.15%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. KHRN.CA Valuation Analysis
4.1 Price/Earnings Ratio
- KHRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KHRN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as KHRN's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.88%
EPS Next 3Y25.99%
5. KHRN.CA Dividend Analysis
5.1 Amount
- KHRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KHRN.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:KHRN (5/5/2023, 7:00:00 PM)
0.04
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.47%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.19M
Revenue(TTM)16.14M
Net Income(TTM)-30.66M
Analysts45.71
Price Target0.1 (150%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)0.99%
Max EPS beat(2)0.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.31%
Min Revenue beat(2)-30.18%
Max Revenue beat(2)-16.44%
Revenue beat(4)1
Avg Revenue beat(4)-33.87%
Min Revenue beat(4)-93.32%
Max Revenue beat(4)4.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.27 | ||
| P/tB | 0.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.09
BVpS0.15
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.51% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.81%
GM growth 5YN/A
F-Score2
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 143.78% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z | -5.28 |
F-Score2
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)345.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.56%
EPS Next Y39.13%
EPS Next 2Y31.88%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)38.2%
Revenue growth 3Y143%
Revenue growth 5YN/A
Sales Q2Q%-3.82%
Revenue Next Year36.43%
Revenue Next 2Y38.09%
Revenue Next 3Y45.7%
Revenue Next 5Y40.15%
EBIT growth 1Y14.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.73%
EBIT Next 3Y30.54%
EBIT Next 5YN/A
FCF growth 1Y43.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A
KHIRON LIFE SCIENCES CORP / KHRN.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of KHIRON LIFE SCIENCES CORP (KHRN.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to KHRN.CA.
Can you provide the valuation status for KHIRON LIFE SCIENCES CORP?
ChartMill assigns a valuation rating of 3 / 10 to KHIRON LIFE SCIENCES CORP (KHRN.CA). This can be considered as Overvalued.
What is the profitability of KHRN stock?
KHIRON LIFE SCIENCES CORP (KHRN.CA) has a profitability rating of 0 / 10.
How financially healthy is KHIRON LIFE SCIENCES CORP?
The financial health rating of KHIRON LIFE SCIENCES CORP (KHRN.CA) is 1 / 10.